Cantor Fitzgerald Starts NantHealth (NH) at Overweight

Cantor Fitzgerald initiates coverage on NantHealth (NASDAQ: NH) with a Overweight rating and a price target of $17.00.

Analyst Steven Halper commented, "We initiate coverage of Nanthealth, Inc. (NH) with an Overweight rating and $17 PT in 12 months. NantHealth has developed a unique cancer screening test, which we believe is poised to change cancer care. The test, known as GPS Cancer, is part of a cancer treatment ecosystem which includes decision support capabilities and payer connectivity. Genomic Proteomic Spectrometry (GPS) Cancer enables the diagnosis of tumors at the molecular level by measuring the genome and proteomes of the tumors. The results are then able to identify the most effective treatment options for patients. GPS Cancer reduces the amount of guesswork by physicians, decreases the use of inappropriate therapies and ultimately reduces the cost of care. The company continues to add new payer and employer relationships, but the ramp since launch has been slower than the company originally expected. The slower ramp does not take away our enthusiasm for the company's strategy, however. Our DCF model reflects high rates of growth, but we believe our discount rate assumption adequately reflects the risk to our estimates."

For an analyst ratings summary and ratings history on NantHealth click here. For more ratings news on NantHealth click here.

Shares of NantHealth closed at $10.31 yesterday.

You May Also Be Interested In

• Northland Starts Bitfarms Ltd. (BITF) at Outperform
• Meta Platforms Inc. (META) PT Lowered to $575 at UBS, 'shares are offering a 3-to-1 skew'
• Amazon.com (AMZN) PT Raised to $215 at UBS